Pfizer Says Its COVID Pill 90 Percent Effective

Pfizer said Friday that its experimental antiviral pill for COVID-19 cut hospitalization and death rates by nearly 90 percent in high-risk adults.

Pfizer's study was stopped when 774 adults had been treated for 28 days.

Among those who took an inactive substance, or placebo, there were 27 hospitalizations with seven deaths.

Pfizer said adults in the study were considered high risk for hospitalization.

They were unvaccinated and showed signs, or symptoms, of mild to moderate COVID-19.

The study shows an 89 percent reduction among patients treated within three days of showing symptoms.

A larger study of 1219 people also shows an 85 percent reduction among those treated within five days.

In that study, six people who received the Pfizer medication were hospitalized.

No one in that group died.

There were 41 hospitalizations and 10 deaths in the placebo group.

The company said it will ask the FDA and international health officials to approve the pill as soon as possible.

The treatment, called Paxlovid, consists of three pills given twice a day for five days.

Last month, drugmaker Merck announced study results of an antiviral pill it produced.

It cut rates of hospitalization and death by 50 percent.

This week, Britain approved that pill for emergency use.

The FDA is currently considering whether to approve it for emergency use in the U.S.

Last year, Pfizer researchers started studying it for COVID-19.

The FDA has already approved several treatments for COVID-19.

But all of them must be injected by healthcare workers.

Pills can be taken at home and are easier to send around the world.

Pfizer said it could produce more than 180,000 treatments by the end of 2021 and at least 50 million by the end of 2022.